# US 2021/0332118 A1 · Monoclonal antibody and antigens for diagnosing and treating lung disease and injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332118 A1
- Document ID: US20210332118A1
- Status: Published application
- Kind: A1
- Application number: 17/198,031
- Filed: 2021-03-10
- Published: 2021-10-28
- Earliest claimed: 2011-06-08
- Assignees: Indiana University Research and Technology Corporation; The United States Government as represented by the Department of Veterans Affairs
- Applicants: Indiana University Research and Technology Corporation; The United States Government AS Represented By the Department of Veterans Affairs
- Inventors: Matthias Clauss; Irina Petrache; Robert Voswinckel
- Web page: https://patentgrep.com/patent/US20210332118A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.

## Claims

### Claim 1

A method for treating a patient having emphysema or COPD comprising administering a therapeutically effective amount of an EMAP II neutralizing antibody.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising generating the antibody by:
contacting the immune system of a mammal with a polypeptide consisting of SEQ ID NO: 12; and selecting a B-cell from the mammal;
wherein the B-cell produces antibodies that bind to endothelial monocyte activating protein II (EMAP II).

### Claim 3 (depends on 2)

The method according to claim 2, wherein contacting the immune system of the mammal comprises immunizing the mammal.

### Claim 4 (depends on 2)

The method according to claim 2, wherein selecting a B-cell from the mammal comprises isolating B-cells from the mammal, fusing the B-cells with myeloma cells thereby forming hybridomas, and selecting at least one hybridoma.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the at least one hybridoma is selected by testing hybridoma supernatant for binding of EMAP II by enzyme linked immunosuppression assay (ELISA).

### Claim 6 (depends on 1)

The method according to claim 1, wherein the EMAP II neutralizing antibody comprises:
a heavy chain variable region, wherein said heavy chain variable region includes at least a portion of a first polypeptide according to SEQ. ID. NO. 2; and
a light chain variable region, wherein said light chain variable region includes at least a portion of a second polypeptide according to SEQ. ID. NO. 3, wherein said antibody is humanized and the humanized antibody binds to human EMAPII.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said first polypeptide has at least 99 percent homology to SEQ. ID. NO. 2, and said second polypeptide has at least 99 percent homology to SEQ. ID. NO. 3.

### Claim 8 (depends on 6)

The method according to claim 6, wherein said first polypeptide has at least 95 percent identity to SEQ. ID. NO. 2 and said second polypeptide has at least 95 percent identity to SEQ. ID. NO. 3.

### Claim 9 (depends on 6)

The method according to claim 6, wherein said first polypeptide has at least 99 percent identity to SEQ. ID. NO. 2 and said second polypeptide has at least 99 percent identity to SEQ. ID. NO. 3.

### Claim 10 (depends on 6)

The method according to claim 6, wherein said first polypeptide is SEQ. ID. NO. 2 and said second polypeptide is SEQ. ID. NO. 3.
